Nicolas R. Barthelemy, PhD

Washington University in St. Louis (WU)

My lab pioneers the development of mass spectrometry-based techniques for advanced tau protein characterization. By employing highly sensitive and specific measures of modified and unmodified tau species in tissue and biofluids, we have uncovered critical insights into neurodegenerative pathology. Our research led to the first demonstration of tau truncation in biofluids, the discovery of p-tau217 as a premier marker of amyloid deposition in Alzheimer’s Disease (AD), and the establishment of p-tau205 as a marker of late-stage soluble tau abnormality. Currently, we are developing novel assays to identify and quantify diverse forms of tau pathologies.